Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Sells 7,800 Shares of Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $8.83, for a total value of $68,874.00. Following the completion of the sale, the insider directly owned 4,803,541 shares in the company, valued at approximately $42,415,267.03. This represents a 0.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total value of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total value of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total value of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total value of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.
• On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.15, for a total value of $396,994.65.
• On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.04, for a total transaction of $1,250,260.20.
• On Thursday, July 30th, L1 Capital Pty Ltd sold 558,633 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.20, for a total transaction of $4,580,790.60.
• On Monday, July 27th, L1 Capital Pty Ltd sold 232,817 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.19, for a total transaction of $1,906,771.23.

Anteris Technologies Global Trading Down 1.5%

NASDAQ AVR opened at $8.61 on Tuesday. The firm’s fifty day moving average price is $9.05 and its two-hundred day moving average price is $7.64. Anteris Technologies Global Corp. has a 1 year low of $3.30 and a 1 year high of $11.06. The firm has a market capitalization of $839.13 million, a P/E ratio of -4.42 and a beta of 1.79.

Anteris Technologies Global (NASDAQ:AVR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The firm had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period last year, the business earned ($0.58) EPS. On average, research analysts anticipate that Anteris Technologies Global Corp. will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Anteris Technologies Global

Several hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its position in shares of Anteris Technologies Global by 76.9% in the third quarter. Russell Investments Group Ltd. now owns 6,536 shares of the company’s stock valued at $29,000 after acquiring an additional 2,841 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Anteris Technologies Global in the 1st quarter valued at about $32,000. BNP Paribas Financial Markets grew its position in shares of Anteris Technologies Global by 83.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,469 shares of the company’s stock worth $43,000 after purchasing an additional 4,302 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Anteris Technologies Global by 35.7% during the third quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock worth $48,000 after purchasing an additional 2,798 shares during the period. Finally, Duncan Williams Asset Management LLC bought a new position in shares of Anteris Technologies Global during the fourth quarter worth approximately $54,000.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Barclays raised their price objective on Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Wall Street Zen upgraded Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a report on Friday, August 14th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Anteris Technologies Global currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.